The HER2-low-positive tumors had a significantly lower pathological complete response rate than HER2-0 tumors, but the 3-year overall survival of HER2-low-positive BC was significantly better than HER2-0 BC (11). This evidence concerns the gene ERBB2 and breast cancer.